Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
30

Inclusion Criteria

Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
Understand and provide written informed consent.
Albumin ≥ 3 g/dL.
...
Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
Understand and provide written informed consent.
Albumin ≥ 3 g/dL.
Men and women 18 years of age at the time of signing the informed consent document with a diagnosis of β-thalassemia major (including all subtypes) or β-thalassemia intermedia.
Agreement to adhere to the study visit schedule, understand and comply with all protocol requirements.
Aspartate Aminotransferase (AST) or Alanine Transaminase (ALT) no greater than 3 x upper limit of normal (ULN);
Average transfusion requirement of at least 2 units/30 days of pRBCs (Gale, 2011) confirmed for a minimum of 168 days (six months) immediately preceding enrollment (study Day 1, first Dose);
No transfusion-free period of more than 45 consecutive days during the 168 days immediately preceding enrollment (study Day 1, first Dose);
Females of childbearing potential participating in the study are to use highly effective methods of birth control during study participation and for 112 days (approximately five times the mean terminal half-life of sotatercept [23 days] based on multiple-dose PK data) following the last dose of sotatercept. FCBP must have a negative serum beta Human Chorionic Gonadotropin (β-HCG) pregnancy test within three days of Sotatercept dosing (Day 1). Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept. A FCBP is a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or who has not been postmenopausal for at least 24 consecutive months (i.e., who has had menses at some time in the preceding 24 months).
For non-transfusion dependent subjects: non-transfusion dependency is defined as a transfusion free for a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose), with the exception of ≤ to one episode of transfusion in the period of a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose) (One episode of transfusion is defined as ≤ 4 transfusion units administered, occurred within 42 days [first transfusion is counted as day 1] due to concurrent illness [e.g. infection], [Guidelines Clin Management of Thalassaemia, 2008]). (This inclusion criteria is not valid for France).
Males must agree to use a latex condom during any sexual contact with FCBSs while participating in the study and for 112 days following the last dose of Sotatercept, even if he has undergone a successful vasectomy. Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept.
Prior transfusion hemoglobin levels ≤ 10.5 g/dL.
Serum creatinine ≤ 1.5 x ULN.

Exclusion Criteria

Adrenal insufficiency.
Evidence of active Hepatitis C antibody (HCV), Hepatitis B surface antigen (HBsAg and HB core Ab), or Human Immunodeficiency Virus (HIV) antibody.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
...
Adrenal insufficiency.
Evidence of active Hepatitis C antibody (HCV), Hepatitis B surface antigen (HBsAg and HB core Ab), or Human Immunodeficiency Virus (HIV) antibody.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
Use of an Erythropoiesis Stimulating Agent (ESA) within the 28 days prior to enrollment (study Day 1, first Dose).
Heart disease with ejection fraction ≥ Grade 2 according to NCI CTCAE version 4.0 (current active minor version);
Subjects who started bisphosphonates within the last three months prior to subject enrollment (study Day 1, first Dose).
Cardiac arrhythmia which requires treatment (i.e. atrial fibrillation).
Heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher (Appendix C).
Major risk of heart failure, confirmed with myocardiac T2* ≤ 10 ms. Myocardiac T2* performed in the last one and a half years prior to subject enrollment (study Day 1, first Dose) will be considered valid.
Treatment with another investigational drug or device < 28 days prior to study entry.
Liver disease with ALT > 3x ULN or histopathological evidence of liver cirrhosis on liver biopsy;
Major surgery within 30 days prior to study Day 1 (subjects must have completely recovered from any previous surgery prior to study Day 1).
Kidney disease with a calculated creatinine clearance < 40 mL/min (Cockcroft-Gault formula);
Subjects on anticoagulant therapy, such as warfarin.
Pulmonary fibrosis or pulmonary hypertension as confirmed by a specialist.
Pregnant or lactating females.
Uncontrolled hypertension. Controlled hypertension for this protocol is considered ≤ Grade 1 according to NCI CTCAE version 4.0 (current active minor version) (Appendix B).
Subjects on hydroxyurea treatment for which the dose was changed in the last one year prior to subject enrollment (study Day 1, first Dose).
Known history of thromboembolic events ≥ Grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (current active minor version).
Subjects with insulin dependent diabetes.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the Investigational Product (see Investigator Brochure).

Summary

Conditions
  • Beta Thalassemia Intermedia
  • Beta Thalassemia Major
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
Understand and provide written informed consent.
Albumin ≥ 3 g/dL.
...
Performance status: Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
Understand and provide written informed consent.
Albumin ≥ 3 g/dL.
Men and women 18 years of age at the time of signing the informed consent document with a diagnosis of β-thalassemia major (including all subtypes) or β-thalassemia intermedia.
Agreement to adhere to the study visit schedule, understand and comply with all protocol requirements.
Aspartate Aminotransferase (AST) or Alanine Transaminase (ALT) no greater than 3 x upper limit of normal (ULN);
Average transfusion requirement of at least 2 units/30 days of pRBCs (Gale, 2011) confirmed for a minimum of 168 days (six months) immediately preceding enrollment (study Day 1, first Dose);
No transfusion-free period of more than 45 consecutive days during the 168 days immediately preceding enrollment (study Day 1, first Dose);
Females of childbearing potential participating in the study are to use highly effective methods of birth control during study participation and for 112 days (approximately five times the mean terminal half-life of sotatercept [23 days] based on multiple-dose PK data) following the last dose of sotatercept. FCBP must have a negative serum beta Human Chorionic Gonadotropin (β-HCG) pregnancy test within three days of Sotatercept dosing (Day 1). Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept. A FCBP is a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or who has not been postmenopausal for at least 24 consecutive months (i.e., who has had menses at some time in the preceding 24 months).
For non-transfusion dependent subjects: non-transfusion dependency is defined as a transfusion free for a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose), with the exception of ≤ to one episode of transfusion in the period of a minimum of 168 days immediately preceding enrollment (study Day 1, first Dose) (One episode of transfusion is defined as ≤ 4 transfusion units administered, occurred within 42 days [first transfusion is counted as day 1] due to concurrent illness [e.g. infection], [Guidelines Clin Management of Thalassaemia, 2008]). (This inclusion criteria is not valid for France).
Males must agree to use a latex condom during any sexual contact with FCBSs while participating in the study and for 112 days following the last dose of Sotatercept, even if he has undergone a successful vasectomy. Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept.
Prior transfusion hemoglobin levels ≤ 10.5 g/dL.
Serum creatinine ≤ 1.5 x ULN.

Exclusion Criteria

Adrenal insufficiency.
Evidence of active Hepatitis C antibody (HCV), Hepatitis B surface antigen (HBsAg and HB core Ab), or Human Immunodeficiency Virus (HIV) antibody.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
...
Adrenal insufficiency.
Evidence of active Hepatitis C antibody (HCV), Hepatitis B surface antigen (HBsAg and HB core Ab), or Human Immunodeficiency Virus (HIV) antibody.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
Use of an Erythropoiesis Stimulating Agent (ESA) within the 28 days prior to enrollment (study Day 1, first Dose).
Heart disease with ejection fraction ≥ Grade 2 according to NCI CTCAE version 4.0 (current active minor version);
Subjects who started bisphosphonates within the last three months prior to subject enrollment (study Day 1, first Dose).
Cardiac arrhythmia which requires treatment (i.e. atrial fibrillation).
Heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher (Appendix C).
Major risk of heart failure, confirmed with myocardiac T2* ≤ 10 ms. Myocardiac T2* performed in the last one and a half years prior to subject enrollment (study Day 1, first Dose) will be considered valid.
Treatment with another investigational drug or device < 28 days prior to study entry.
Liver disease with ALT > 3x ULN or histopathological evidence of liver cirrhosis on liver biopsy;
Major surgery within 30 days prior to study Day 1 (subjects must have completely recovered from any previous surgery prior to study Day 1).
Kidney disease with a calculated creatinine clearance < 40 mL/min (Cockcroft-Gault formula);
Subjects on anticoagulant therapy, such as warfarin.
Pulmonary fibrosis or pulmonary hypertension as confirmed by a specialist.
Pregnant or lactating females.
Uncontrolled hypertension. Controlled hypertension for this protocol is considered ≤ Grade 1 according to NCI CTCAE version 4.0 (current active minor version) (Appendix B).
Subjects on hydroxyurea treatment for which the dose was changed in the last one year prior to subject enrollment (study Day 1, first Dose).
Known history of thromboembolic events ≥ Grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (current active minor version).
Subjects with insulin dependent diabetes.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the Investigational Product (see Investigator Brochure).

Tracking Information

NCT #
NCT01571635
Collaborators
Not Provided
Investigators
Study Director: Abderrahmanne Laadem, CRP Celgene
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024